

OMICROHN

A study to help choose the best treatment for Crohn's disease


Why is this study being done?

There are several medicines available for Crohn's disease. However, it is not always clear which medicine will work best for each person. Because of this, some people need to try different treatments before finding one that works well.

Researchers have developed a blood

test that may help predict whether **vedolizumab** or **ustekinumab** is more likely to work for a patient.

The OmiCrohn study will look at whether this blood test can help doctors choose the treatment most likely to work more effectively than standard care.



Who can participate?

You may be able to join the study if you:

Have active Crohn's disease

Can be treated with vedolizumab or ustekinumab

Have used no more than one biological medicine before

Other eligibility criteria apply and will be assessed by the study team

What will researchers measure?

- Less inflammation in the bowel (endoscopy)
- Fewer Crohn's symptoms, measured through questionnaires

What do researchers expect?

Researchers hope that using the blood test will:

- Reduce symptoms
- Reduce inflammation in the bowel
- Help more patients achieve remission (when the disease is under control)

What could this mean for patients?

If the blood test can help identify the best treatment sooner, patients may benefit from:

- Faster relief of symptoms
- Fewer hospital stays
- Fewer operations
- More personalised treatment
- A better quality of life

**More information on
how to participate:**



Participation is voluntary and you can withdraw from the study at any time.